Research ArticleBasic Science Investigations
A 99mTc-Labeled Ligand of Carbonic Anhydrase IX Selectively Targets Renal Cell Carcinoma In Vivo
Nikolaus Krall, Francesca Pretto, Martin Mattarella, Cristina Müller and Dario Neri
Journal of Nuclear Medicine June 2016, 57 (6) 943-949; DOI: https://doi.org/10.2967/jnumed.115.170514
Nikolaus Krall
1Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, ETH Zürich, Zurich, Switzerland
Francesca Pretto
2Philochem AG, Otelfingen (ZH), Switzerland; and
Martin Mattarella
2Philochem AG, Otelfingen (ZH), Switzerland; and
Cristina Müller
3Research Department Biology and Chemistry, Paul Scherrer Institut, Center for Radiopharmaceutical Sciences, Villigen-PSI, Switzerland
Dario Neri
1Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, ETH Zürich, Zurich, Switzerland
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 57, Issue 6
June 1, 2016
A 99mTc-Labeled Ligand of Carbonic Anhydrase IX Selectively Targets Renal Cell Carcinoma In Vivo
Nikolaus Krall, Francesca Pretto, Martin Mattarella, Cristina Müller, Dario Neri
Journal of Nuclear Medicine Jun 2016, 57 (6) 943-949; DOI: 10.2967/jnumed.115.170514
Jump to section
Related Articles
Cited By...
- Immunotherapy with Immunocytokines and PD-1 Blockade Enhances the Anticancer Activity of Small Molecule-Drug Conjugates Targeting Carbonic Anhydrase IX
- A Microdosing Study with 99mTc-PHC-102 for the SPECT/CT Imaging of Primary and Metastatic Lesions in Renal Cell Carcinoma Patients
- Immunotherapy with immunocytokines and PD-1 blockade enhances the anticancer activity of small molecule-drug conjugates targeting carbonic anhydrase IX
- Sortase-mediated site-specific modification of interleukin-2 for the generation of a tumor targeting acetazolamide-cytokine conjugate
- Evaluation of Nonpeptidic Ligand Conjugates for the Treatment of Hypoxic and Carbonic Anhydrase IX-Expressing Cancers
- Acetazolamide Serves as Selective Delivery Vehicle for Dipeptide-Linked Drugs to Renal Cell Carcinoma